In this micro learning programme, you'll learn about PARP inhibitors in prostate cancer from medical experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno. 

Learning resources include videos, slides, flashcards and assessments. Complete both modules to earn your CME credit.

What you'll learn

 

 

Clinical takeaways:

  • PARP inhibitors are effective drugs as monotherapy in mCRPC patients with HRR alterations
  • Genetic testing is important to help with treatment decision-making and for understanding inherited risk
  • BRCA mutations are associated with poor outcomes in mCRPC patients
  • Patients with tumours harbouring BRCA1/BRCA2 alterations appear to derive the greatest clinical benefit from PARPi, but patients with other HRR alterations also derive benefit
  • PARP inhibitors combined with novel hormonal agents are effective as a first-line treatment option for mCRPC patients with an HRR mutation. Certain combinations, such as olaparib plus abiraterone and talazoparib plus enzalutamide, have also shown benefits in patients regardless of their HRR status

Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.

Assoc. Prof. Alicia Morgans has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Myovant, Novartis, Pfizer, Sanofi and Telix. 

Dr Pasquale Rescigno is Clinical Senior Lecturer at the Translational and Clinical Research Institute at Newcastle University, UK. He is the former Head of the Translational and Clinical Trial Team on GU Cancers at the Istituto di Candiolo FPO-IRCCS (Candiolo Cancer Institute), Clinical Research Fellow at the Institute of Cancer Research (London), and Prostate Cancer Foundation Young Investigator awardee.  

His research mainly focuses on the study of mechanisms/pathways that are disrupted in prostate cancer (such as PTEN/PI3K/AKT, TP53 and RB1), and on the identification and validation of predictive, prognostic and efficacy-response biomarkers for novel agents targeting the PI3K/AKT, DNA repair systems and the PD-1/PDL-1 pathways.

He has served as Principal and Sub-investigator of several phase I/II/III Clinical Trials and designed and is the Clinical Coordinator and Principal Investigator of UK and Italian national research projects (MAESTRO, an umbrella trial and PERSEUS1 in the UK; BITCOIN and BRIDGE in Italy).

More recently, his research activity focused on the study of gut microbiome in prostate cancer.
Programme summary
Other modules in this series
PARP inhibitors in prostate cancer and the rationale behind combination treatment

PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

PARP inhibitors in prostate cancer and the rationale behind combination treatment

PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Current Module
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for 0.5 ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
Precision oncology in prostate and gastric cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
podcast Podcast

Episode

2

of 2

episode
Oncology 
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

Medical experts discuss how to approach sequencing in clinical practice

Experts
Prof. Arndt Vogel, Dr Lorenza Rimassa, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery Global Liver Institute
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
Testing to treatment of BRAF-mutant metastatic NSCLC

Medical experts share their insights on testing and treatment

Experts
Prof. David Planchard, Dr Federico Cappuzzo
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. This content is intended for HCPs outside the UK & ROI only.
podcast Podcast

Episode

1

of 2

episode
Oncology 
HCC podcast series part 1: The use of IO in unresectable HCC

Medical experts discuss safety and efficacy of IO and IO combinations, clinical trial data, and best practice

Experts
Dr Rachna Shroff, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The emerging role of artificial intelligence in precision oncology

Expert opinion on the clinical application of artificial intelligence (AI)

Experts
Prof. Albrecht Stenzinger
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
BRAF-mutated CRC: from testing to treatment

Medical experts share insights and review key clinical trials

Experts
Prof. Sebastian Stintzing, Dr Thomas Winder
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre. This content is not intended for HCPs within the UK.